Michael Richman
Founder en NEXTCURE, INC. .
Fortuna: 883 805 $ al 31/03/2024
Perfil
Michael S.
Richman was the founder of Amplimmune, Inc. (founded in 2007) and NextCure, Inc. (founded in 2015), where he held the titles of President & Chief Executive Officer and President, Chief Executive Officer & Director, respectively.
He currently holds positions as Director at Madison Vaccines, Inc. (since 2014) and Independent Director at Pieris Pharmaceuticals, Inc. (since 2014).
He also served as Chief Operating Officer & Executive Vice President at MacroGenics, Inc. (2002-2007) and Senior Vice President-Corporate Development at Medimmune, Inc. Mr. Richman has an undergraduate degree from the University of California, Davis, and a graduate degree from San Francisco State University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NEXTCURE, INC.
1.42% | 29/03/2024 | 396 325 ( 1.42% ) | 883 805 $ | 31/03/2024 |
| 21/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Michael Richman
| Empresas | Cargo | Inicio |
|---|---|---|
| PIERIS PHARMACEUTICALS, INC. | Director/Board Member | 17/12/2014 |
| NEXTCURE, INC. | Founder | 01/12/2015 |
Madison Vaccines, Inc.
 Madison Vaccines, Inc. Pharmaceuticals: MajorHealth Technology Madison Vaccines, Inc. develops vaccines for patients with prostate cancer. It is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines. The firm develops immunological therapies in patients with minimal residual disease, and for whom the mechanism of action of vaccines is ideally suited. The company was founded by Richard R. Lesniewski and Douglas G. McNeel in 2012 and is headquartered in Madison, WI. | Director/Board Member | 01/05/2014 |
Antiguos cargos conocidos de Michael Richman.
| Empresas | Cargo | Fin |
|---|---|---|
Opexa Therapeutics, Inc.
 Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Director/Board Member | 19/09/2017 |
| GENVEC INC | Chairman | 16/06/2017 |
Amplimmune, Inc.
 Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | Chief Executive Officer | 01/07/2015 |
Janssen Oncology, Inc.
 Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Janssen Oncology, Inc. engages in the development of pharmaceutical products for the treatment of cancer. It conducts pharmaceutical product trials. The company is headquartered in Los Angeles, CA. | Director/Board Member | 01/07/2009 |
| MACROGENICS, INC. | Chief Operating Officer | 01/05/2007 |
Formación de Michael Richman.
| San Francisco State University | Graduate Degree |
| University of California, Davis | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| MACROGENICS, INC. | Health Technology |
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| NEXTCURE, INC. | Health Technology |
| Empresas privadas | 11 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
Cougar Biotechnology, Inc. /Old/
 Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | Health Technology |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | Health Technology |
| PharmaFrontiers Corp. | Health Technology |
Pieris AG
 Pieris AG BiotechnologyHealth Technology Pieris AG develops and markets Anticalin-brand proteins. The firm specializes in the research and development of its Anticalin technology, with focus on deriving therapeutic proteins from human lipocalins. It focuses on solving pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms. It offers a pipeline of Anticalin therapeutics that has active and multi-program research and development collaborations with biopharmaceutical companies. The company was founded by Arne Skerra, Steffen Schlehuber, and Claus Schalper in 2001 and is headquartered in Freising, Germany. | Health Technology |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Health Technology |
Madison Vaccines, Inc.
Madison Vaccines, Inc. Pharmaceuticals: MajorHealth Technology Madison Vaccines, Inc. develops vaccines for patients with prostate cancer. It is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines. The firm develops immunological therapies in patients with minimal residual disease, and for whom the mechanism of action of vaccines is ideally suited. The company was founded by Richard R. Lesniewski and Douglas G. McNeel in 2012 and is headquartered in Madison, WI. | Health Technology |
| Medimmune, Inc. | Health Technology |
Janssen Oncology, Inc.
Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Janssen Oncology, Inc. engages in the development of pharmaceutical products for the treatment of cancer. It conducts pharmaceutical product trials. The company is headquartered in Los Angeles, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Michael Richman
